Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

225 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial.
Pettitt AR, Jackson R, Carruthers S, Dodd J, Dodd S, Oates M, Johnson GG, Schuh A, Matutes E, Dearden CE, Catovsky D, Radford JA, Bloor A, Follows GA, Devereux S, Kruger A, Blundell J, Agrawal S, Allsup D, Proctor S, Heartin E, Oscier D, Hamblin TJ, Rawstron A, Hillmen P. Pettitt AR, et al. Among authors: oates m. J Clin Oncol. 2012 May 10;30(14):1647-55. doi: 10.1200/JCO.2011.35.9695. Epub 2012 Apr 9. J Clin Oncol. 2012. PMID: 22493413 Clinical Trial.
Functional analysis of the ATM-p53-p21 pathway in the LRF CLL4 trial: blockade at the level of p21 is associated with short response duration.
Lin K, Adamson J, Johnson GG, Carter A, Oates M, Wade R, Richards S, Gonzalez D, Matutes E, Dearden C, Oscier DG, Catovsky D, Pettitt AR. Lin K, et al. Among authors: oates m. Clin Cancer Res. 2012 Aug 1;18(15):4191-200. doi: 10.1158/1078-0432.CCR-11-2936. Epub 2012 Jun 6. Clin Cancer Res. 2012. PMID: 22675167 Free article.
The gene expression signature associated with TP53 mutation/deletion in chronic lymphocytic leukaemia is dominated by the under-expression of TP53 and other genes on chromosome 17p.
Lin K, Lane B, Carter A, Johnson GG, Onwuazor O, Oates M, Zenz T, Stilgenbauer S, Atherton M, Douglas A, Ebrahimi B, Sherrington PD, Pettitt AR. Lin K, et al. Among authors: oates m. Br J Haematol. 2013 Jan;160(1):53-62. doi: 10.1111/bjh.12092. Epub 2012 Oct 30. Br J Haematol. 2013. PMID: 23110309 Free article.
CYP2B6*6 is an independent determinant of inferior response to fludarabine plus cyclophosphamide in chronic lymphocytic leukemia.
Johnson GG, Lin K, Cox TF, Oates M, Sibson DR, Eccles R, Lloyd B, Gardiner LJ, Carr DF, Pirmohamed M, Strefford JC, Oscier DG, Gonzalez de Castro D, Else M, Catovsky D, Pettitt AR. Johnson GG, et al. Among authors: oates m. Blood. 2013 Dec 19;122(26):4253-8. doi: 10.1182/blood-2013-07-516666. Epub 2013 Oct 15. Blood. 2013. PMID: 24128861 Free article. Clinical Trial.
Total proteome analysis identifies migration defects as a major pathogenetic factor in immunoglobulin heavy chain variable region (IGHV)-unmutated chronic lymphocytic leukemia.
Eagle GL, Zhuang J, Jenkins RE, Till KJ, Jithesh PV, Lin K, Johnson GG, Oates M, Park K, Kitteringham NR, Pettitt AR. Eagle GL, et al. Among authors: oates m. Mol Cell Proteomics. 2015 Apr;14(4):933-45. doi: 10.1074/mcp.M114.044479. Epub 2015 Feb 2. Mol Cell Proteomics. 2015. PMID: 25645933 Free PMC article.
Evaluation of High-Throughput Genomic Assays for the Fc Gamma Receptor Locus.
Hargreaves CE, Iriyama C, Rose-Zerilli MJ, Nagelkerke SQ, Hussain K, Ganderton R, Lee C, Machado LR, Hollox EJ, Parker H, Latham KV, Kuijpers TW, Potter KN, Coupland SE, Davies A, Stackpole M, Oates M, Pettitt AR, Glennie MJ, Cragg MS, Strefford JC. Hargreaves CE, et al. Among authors: oates m. PLoS One. 2015 Nov 6;10(11):e0142379. doi: 10.1371/journal.pone.0142379. eCollection 2015. PLoS One. 2015. PMID: 26545243 Free PMC article.
225 results